Cas9 Stable Cell Line - 786-O
Cat.No. : CSC-RO0223 Host Cell: 786-O
Size: >1x10^6 cells/vial Validation: T7 Endonuclease I assay
Inquire for Price
Cell Line Information
Safety and Packaging
| Cat. No. | CSC-RO0223 |
| Product Type | Cas9 overexpression stable cell line |
| Introduction | Clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 is a gene-editing technology that contains two essential components: a guide RNA (gRNA) to match a target gene, and the Cas9 (CRISPR-associated protein 9) endonuclease which causes a double-stranded DNA break, allowing modifications to the genome via nonhomologous end joining (NHEJ) or homology-directed repair (HDR). |
| Cell Line Information | 786-O-Cas9 cell line is engineered to stably overexpress Cas9 nuclease. The Cas9 nuclease in 786-O-Cas9 cell line has been functionally validated using T7 Endonuclease I assay. In combination with separately transfected sgRNAs, 786-O-Cas9 cell line can be used to efficiently generate targeted genomic modifications including gene knockout, gene knockin, gene mutagenesis, gene tagging etc. It is also an ideal cell line model for sgRNA screening and validation, either individually or in pools. |
| Target Gene | Cas9 |
| Host Cell | 786-O |
| Applications | 1) CRISPR genome editing, such as gene knockout (KO), gene knockin (KI), gene mutagenesis, gene tagging etc. 2) High-throughput sgRNA screening and validation |
| Quality Control | 1) T7E1 assay 2) Mycoplasma detection |
| Size Form | One vial of frozen cells, typically >1x10^6 cells/vial |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Species | Homo sapiens (Human) |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Inquiry
Case Study
Applications
Transcription factors play a critical role in regulating gene expression programs that determine cell identity and disease states. In Renal Cell Carcinoma (RCC), the Core Regulatory Circuitry (CRC) analysis identified PAX8 as a potential oncogene. Functional genomic screens confirmed that silencing PAX8 impairs RCC cell proliferation, while epigenomic studies revealed that PAX8 binds to active enhancer elements that control genes involved in metabolic pathways. One such gene, Ceruloplasmin (CP), was highlighted for its role in PAX8-mediated gene regulation. PAX8's recruitment of histone acetylation at enhancers impacts CP expression, which correlates with RCC cell sensitivity to PAX8 silencing. These findings underscore PAX8 as both an oncogene and a potential biomarker for RCC. The researchers used the 786-O Cas9 stable cell line to explore the effects of PAX8 silencing, utilizing lentiviral constructs for precise genetic modifications.
Figure 1. The researchers employed a combination of RNA-seq, qPCR, and Western blot analysis to study PAX8 regulation of CP in RCC cells. Using the 786-O Cas9 stable cell line, they silenced PAX8 and examined its impact on CP expression and enhancer activity, validating results with ChIP-qPCR and luciferase assays. (Bleu M, et al., 2019)
Creative Biogene offers similar Cas9 stable cell line products, like the 786-O Cas9 line, enabling targeted gene editing for cancer research, including studies on gene function, drug resistance, and biomarker discovery.
The Cas9 Stable Cell Line - 786-O is a renal cell carcinoma cell line engineered to stably express the Cas9 endonuclease, an enzyme that enables precise gene editing. This cell line is particularly beneficial for research in gene function, cancer biology, and the development of targeted therapies for kidney cancer.
（1）Functional Genomics of Renal Cancer:
The 786-O Cas9 Stable Cell Line is used to investigate the genomic landscape of renal cell carcinoma. Researchers can perform genome-wide screens to identify genes that drive cancer growth or are involved in drug resistance, leading to a better understanding of renal cancer biology and the identification of novel therapeutic targets.
（2）Personalized Medicine Approaches:
By utilizing the Cas9 system to edit the genome of 786-O cells, researchers can model specific genetic mutations found in patient tumors. This allows for the testing of personalized treatment strategies, potentially leading to more effective and tailored therapies for kidney cancer patients.
（3）Drug Screening and Development:
The Cas9 expression in 786-O cells facilitates the screening of compounds for their potential to inhibit kidney cancer cell growth or induce apoptosis. By knocking out or modifying genes associated with cancer progression, researchers can assess the efficacy of potential drugs and identify new molecular targets for cancer therapy.
For research use only. Not intended for any clinical use.
